AOD9604 Side Effects: What Clinical Trials Reported
AOD9604 Side Effects: What Clinical Trials Reported
AOD9604 side effects data comes from six randomized double-blind placebo-controlled human trials across approximately 900 participants, with dose durations up to 24 weeks. The aggregate finding: the adverse event profile was indistinguishable from placebo. No serious drug-related adverse events were reported. No drug-related withdrawals occurred [4]. This page is the spec-sheet reading of that safety record.
Is AOD9604 safe? What clinical trials found
Phase I and Phase IIb human trials found AOD9604 well-tolerated at doses up to 1 mg/day orally and up to 400 mcg/kg intravenously. Adverse events — including mild headache and transient GI symptoms — were comparable to placebo in frequency and severity. Zero participants developed anti-AOD9604 antibodies. No effect on IGF-1 or glucose metabolism was detected at any tested dose [4][5][6][13].
What Are the Documented Side Effects of AOD9604?
Reported adverse events in clinical trials, in order of frequency:
Mild headache — most commonly reported event; frequency and severity equivalent to placebo group [4].
Transient gastrointestinal effects — diarrhea, flatulence, nausea; all mild-to-moderate, self-resolving, comparable to placebo frequency [4].
Injection-site reactions — redness, localized swelling, mild pain — observed when subcutaneous administration route was used in research settings; all mild-to-moderate and resolved without intervention [4].
Notably absent from the AOD9604 safety record: no blood glucose disruption, no IGF-1 elevation, no immunogenic response in any published trial [5][6][13].
AOD9604 Peptide Adverse Event Profile
The adverse event profile holds across both oral and intravenous administration. Six trials across approximately 900 subjects: zero serious drug-related adverse events, zero drug-related withdrawals, adverse event rates for mild headache and transient GI symptoms distributed equally between treatment and placebo groups [4]. The absence of immunogenicity — zero anti-drug antibodies across all participants — is attributed to the compound's structural homology with an endogenous human protein sequence [13].
Does AOD9604 Affect Glucose or Insulin?
No significant effect on blood glucose or insulin sensitivity was detected in any treatment group across all AOD9604 clinical trials. Oral glucose tolerance testing showed no adverse changes from baseline at any dose [6]. At the 1 mg oral dose in the Phase IIa trial, a trend toward benefit was observed in subjects with impaired glucose tolerance — reduced prevalence compared to placebo [21]. This is consistent with AOD9604's mechanism: it does not interact with insulin signaling pathways or pancreatic beta-cell function.
What Happens When You Stop Taking AOD9604?
No rebound or withdrawal effects were documented in clinical trial discontinuation periods across six AOD9604 trials [20]. As a peptide with no HPA-axis receptor agonism and no hormonal dependency mechanism, physiological dependency is not a mechanism that was studied or observed. No withdrawal adverse events were reported in any discontinuation window.
AOD9604 Side Effects and Safety Profile — Chronic Toxicology Data
Chronic animal toxicology studies: no genotoxic activity detected (Ames assay, chromosomal aberration assay, bone marrow micronucleus test). Oral NOAEL established at 100 mg/kg/day in 6-month rat studies and 50 mg/kg/day in 9-month cynomolgus monkey studies. No treatment-related deaths in any study [9]. These are the pre-clinical safety parameters that supported the human trial program. For the AOD9604 side effects and safety profile overview, see the sections above.
FDA PCAC December 2024 — 503A Compounding Review
The most recent regulatory development: the FDA Pharmacy Compounding Advisory Committee convened December 4, 2024 to review AOD9604 free base and AOD9604 acetate for inclusion on the 503A bulk drug substances list for compounding pharmacies. The nominator had previously withdrawn the nomination in September 2024. The committee's review noted concerns about limited long-term safety data, peptide impurities, and potential immunogenicity — though all published clinical trial data showed zero immunogenicity across approximately 900 subjects [RS1]. As of the date of this publication, AOD9604's compounding status remains under regulatory review. Researchers and users should verify current FDA regulatory standing independently.